Merck Halts Preladenant Development In Parkinson’s Following Phase III Failures
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.